These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
882 related articles for article (PubMed ID: 30314978)
1. Empagliflozin and Kidney Function Decline in Patients with Type 2 Diabetes: A Slope Analysis from the EMPA-REG OUTCOME Trial. Wanner C; Heerspink HJL; Zinman B; Inzucchi SE; Koitka-Weber A; Mattheus M; Hantel S; Woerle HJ; Broedl UC; von Eynatten M; Groop PH; J Am Soc Nephrol; 2018 Nov; 29(11):2755-2769. PubMed ID: 30314978 [TBL] [Abstract][Full Text] [Related]
2. Effect of dapagliflozin on the rate of decline in kidney function in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial. Heerspink HJL; Jongs N; Chertow GM; Langkilde AM; McMurray JJV; Correa-Rotter R; Rossing P; Sjöström CD; Stefansson BV; Toto RD; Wheeler DC; Greene T; Lancet Diabetes Endocrinol; 2021 Nov; 9(11):743-754. PubMed ID: 34619108 [TBL] [Abstract][Full Text] [Related]
3. Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease. Wanner C; Lachin JM; Inzucchi SE; Fitchett D; Mattheus M; George J; Woerle HJ; Broedl UC; von Eynatten M; Zinman B; Circulation; 2018 Jan; 137(2):119-129. PubMed ID: 28904068 [TBL] [Abstract][Full Text] [Related]
4. Analysis from the EMPA-REG OUTCOME Mayer GJ; Wanner C; Weir MR; Inzucchi SE; Koitka-Weber A; Hantel S; von Eynatten M; Zinman B; Cherney DZI Kidney Int; 2019 Aug; 96(2):489-504. PubMed ID: 31142441 [TBL] [Abstract][Full Text] [Related]
5. Empagliflozin and kidney outcomes in Asian patients with type 2 diabetes and established cardiovascular disease: Results from the EMPA-REG OUTCOME Kadowaki T; Nangaku M; Hantel S; Okamura T; von Eynatten M; Wanner C; Koitka-Weber A J Diabetes Investig; 2019 May; 10(3):760-770. PubMed ID: 30412655 [TBL] [Abstract][Full Text] [Related]
6. Empagliflozin and Cardiovascular and Kidney Outcomes across KDIGO Risk Categories: Levin A; Perkovic V; Wheeler DC; Hantel S; George JT; von Eynatten M; Koitka-Weber A; Wanner C; Clin J Am Soc Nephrol; 2020 Oct; 15(10):1433-1444. PubMed ID: 32994159 [TBL] [Abstract][Full Text] [Related]
7. Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. Wanner C; Inzucchi SE; Lachin JM; Fitchett D; von Eynatten M; Mattheus M; Johansen OE; Woerle HJ; Broedl UC; Zinman B; N Engl J Med; 2016 Jul; 375(4):323-34. PubMed ID: 27299675 [TBL] [Abstract][Full Text] [Related]
8. Empagliflozin Improves Kidney Outcomes in Patients With or Without Heart Failure. Butler J; Zannad F; Fitchett D; Zinman B; Koitka-Weber A; von Eynatten M; Zwiener I; George J; Brueckmann M; Cheung AK; Wanner C Circ Heart Fail; 2019 Jun; 12(6):e005875. PubMed ID: 31163986 [TBL] [Abstract][Full Text] [Related]
9. Ertugliflozin and Slope of Chronic eGFR: Prespecified Analyses from the Randomized VERTIS CV Trial. Cherney DZI; Cosentino F; Dagogo-Jack S; McGuire DK; Pratley R; Frederich R; Maldonado M; Liu CC; Liu J; Pong A; Cannon CP; Clin J Am Soc Nephrol; 2021 Sep; 16(9):1345-1354. PubMed ID: 34497110 [TBL] [Abstract][Full Text] [Related]
10. Pooled analysis of Phase III trials indicate contrasting influences of renal function on blood pressure, body weight, and HbA1c reductions with empagliflozin. Cherney DZI; Cooper ME; Tikkanen I; Pfarr E; Johansen OE; Woerle HJ; Broedl UC; Lund SS Kidney Int; 2018 Jan; 93(1):231-244. PubMed ID: 28860019 [TBL] [Abstract][Full Text] [Related]
11. Effect of Empagliflozin on Left Ventricular Mass in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease: The EMPA-HEART CardioLink-6 Randomized Clinical Trial. Verma S; Mazer CD; Yan AT; Mason T; Garg V; Teoh H; Zuo F; Quan A; Farkouh ME; Fitchett DH; Goodman SG; Goldenberg RM; Al-Omran M; Gilbert RE; Bhatt DL; Leiter LA; Jüni P; Zinman B; Connelly KA Circulation; 2019 Nov; 140(21):1693-1702. PubMed ID: 31434508 [TBL] [Abstract][Full Text] [Related]
12. Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial. Cherney DZI; Zinman B; Inzucchi SE; Koitka-Weber A; Mattheus M; von Eynatten M; Wanner C Lancet Diabetes Endocrinol; 2017 Aug; 5(8):610-621. PubMed ID: 28666775 [TBL] [Abstract][Full Text] [Related]
13. Choice of endpoint in kidney outcome trials: considerations from the EMPA-REG OUTCOME® trial. Perkovic V; Koitka-Weber A; Cooper ME; Schernthaner G; Pfarr E; Woerle HJ; von Eynatten M; Wanner C Nephrol Dial Transplant; 2020 Dec; 35(12):2103-2111. PubMed ID: 31495881 [TBL] [Abstract][Full Text] [Related]
14. Effects of empagliflozin on first and recurrent clinical events in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a secondary analysis of the EMPA-REG OUTCOME trial. McGuire DK; Zinman B; Inzucchi SE; Wanner C; Fitchett D; Anker SD; Pocock S; Kaspers S; George JT; von Eynatten M; Johansen OE; Jamal W; Mattheus M; Elsasser U; Hantel S; Lund SS Lancet Diabetes Endocrinol; 2020 Dec; 8(12):949-959. PubMed ID: 33217335 [TBL] [Abstract][Full Text] [Related]
15. Short-Term Changes in Albuminuria and Risk of Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus: A Post Hoc Analysis of the EMPA-REG OUTCOME Trial. Waijer SW; Xie D; Inzucchi SE; Zinman B; Koitka-Weber A; Mattheus M; von Eynatten M; Inker LA; Wanner C; Heerspink HJL J Am Heart Assoc; 2020 Sep; 9(18):e016976. PubMed ID: 32893717 [TBL] [Abstract][Full Text] [Related]
16. Empagliflozin reduces cardiovascular events, mortality and renal events in participants with type 2 diabetes after coronary artery bypass graft surgery: subanalysis of the EMPA-REG OUTCOME® randomised trial. Verma S; Mazer CD; Fitchett D; Inzucchi SE; Pfarr E; George JT; Zinman B Diabetologia; 2018 Aug; 61(8):1712-1723. PubMed ID: 29777264 [TBL] [Abstract][Full Text] [Related]
17. Cardiac and Kidney Benefits of Empagliflozin in Heart Failure Across the Spectrum of Kidney Function: Insights From EMPEROR-Reduced. Zannad F; Ferreira JP; Pocock SJ; Zeller C; Anker SD; Butler J; Filippatos G; Hauske SJ; Brueckmann M; Pfarr E; Schnee J; Wanner C; Packer M Circulation; 2021 Jan; 143(4):310-321. PubMed ID: 33095032 [TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial. Barnett AH; Mithal A; Manassie J; Jones R; Rattunde H; Woerle HJ; Broedl UC; Lancet Diabetes Endocrinol; 2014 May; 2(5):369-84. PubMed ID: 24795251 [TBL] [Abstract][Full Text] [Related]
19. Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the empa-kidney trial. EMPA-KIDNEY Collaborative Group Lancet Diabetes Endocrinol; 2024 Jan; 12(1):39-50. PubMed ID: 38061371 [TBL] [Abstract][Full Text] [Related]
20. Consistent effects of empagliflozin on cardiovascular and kidney outcomes irrespective of diabetic kidney disease categories: Insights from the EMPA-REG OUTCOME trial. Wanner C; Inzucchi SE; Zinman B; Koitka-Weber A; Mattheus M; George JT; von Eynatten M; Hauske SJ; Diabetes Obes Metab; 2020 Dec; 22(12):2335-2347. PubMed ID: 32744354 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]